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Homicide and Suicide Rates -National Violent Death Reporting System, Six States, 2003
In 2003, CDC instituted a new surveillance system, the National Violent Death Reporting System (NVDRS); the system collects detailed information regarding violent deaths from multiple sources. This report describes preliminary 2003 data from the first six states* that participated in NVDRS and compares these data with 1993-2002 data from the National Vital Statistics System (NVSS). The findings indicate a substantial increase in homicide rates among young males from 2002 to 2003 and substantial increases in both homicide and suicide rates among males from 2000 to 2003. These findings underscore the need for states to have timely information for effective violence-prevention programs.
NVDRS is a state-based, active surveillance system that collects information on all homicides, suicides, deaths of undetermined intent, deaths resulting from legal intervention, and deaths from unintentional firearm injuries. State health departments participating in NVDRS typically identify these violent deaths as their death certificates are filed and then establish details of the cases from medical examiner, coroner, and law enforcement records. Details collected include the circumstances contributing to the deaths, interpersonal relationships, and toxicology results. The first six states to join NVDRS in 2003 accounted for 10% of suicides and 11% of homicides in the United States in 2002.
International Classification of Diseases, Tenth Revision (ICD-10) codes for the underlying cause of deaths in 2003 have not yet been reported to NVDRS from two of the six states. However, trained coders in each state routinely assign a cause of death to all cases by using standard NVDRS definitions after reviewing information from all available sources. The cause of death, as defined by NVDRS, is consistent with the way most medical examiners and coroners assign cause of death. The NVDRS cause of death used for this analysis was consistent with the underlying cause of death from death certificates in approximately 97% of the homicides and suicides for which ICD-10 codes were available. This analysis was restricted to occurrent deaths (i.e., deaths within the state borders of both residents and nonresidents) because of delays in reporting deaths of state residents that occurred out of state. All NVDRS 2003 data are preliminary.
NVDRS data for 2003 were compared with data for 1993-2002 from NVSS for the same six states. In NVSS, a homicide was defined as a death in which the underlying cause was coded as X85-Y09 or Y87.1; these codes exclude deaths attributed to legal intervention, operations of war, or terrorism (1) . A suicide was defined as a death in which the underlying cause was coded as X60-X84 or Y87.0. Deaths that occurred in Oregon as a result of its Death with Dignity Act are not classified as suicides by Oregon law and were excluded from this analysis.
Rates were calculated by using intercensal and postcensal bridged-race population estimates compiled by the National Center for Health Statistics (2) and were age-adjusted to the 2000 standard U.S. population. Rates were also stratified by sex and age. Because of limited death counts in some age groupings, the age categories were collapsed into ages 0-24 years, Editorial Note: During 1993-2000, NVSS data indicate that homicide and suicide rates declined in the United States; the age-adjusted rates of homicide and suicide declined 38% and 13%, respectively. These declines ended with small, consecutive increases in homicide and suicide rates in 2001 and 2002, even after exclusion of the deaths associated with the September 11, 2001, terrorist attacks (3). A similar pattern was observed during 1993-2002 in the six NVDRS states. Although preliminary national homicide and suicide rates did not increase in 2003, preliminary rates typically underestimate final rates for these conditions by 3%-4% (1) . The homicide increase in NVDRS states, however, is consistent with final data from law enforcement reports compiled by the Federal Bureau of Investigation, which indicate an increase in the national homicide rate in 2003 (4) . The homicide rate increase in NVDRS was caused by a substantial increase in homicides among males aged <24 years. Similarly, fluctuations in the national homicide rate in the 1980s and early 1990s were caused by homicides among males aged 15-24 years (5) .
Although NVDRS collects detailed information about circumstances associated with these deaths, determining how risk factors might have changed in recent years with only 1 year of data was not possible. Changes in rates of violence have been attributed to various risk factors (e.g., changes in the economy, the availability of drugs and weapons, and gang violence) (5, 6) , particularly with respect to homicide. NVDRS will monitor future data for changes in the proportions of violent deaths that involve specific risk factors.
The findings in this report are subject to at least three limitations. First, all death rates were based on deaths by place of occurrence rather than place of residence, and some decedents might not have resided in the six states that provided data. However, 2002 NVSS data indicate that the numbers of resident and occurrent homicides in these six states combined differed by only 1.7%, and the difference was only 0.7% with respect to suicides. Therefore, occurrent deaths are acceptable substitutes for resident deaths. Second, preliminary NVDRS data might differ from final NVDRS data if late cases are added to the system. Third, NVDRS data might differ from data generated from NVSS because the NVDRS classification of a death might differ from the way a death is recorded on a death certificate in a limited number of cases. Although only six states began collecting data in 2003, NVDRS is now funding programs in 11 additional states † to collect data on violent deaths and submit these data to CDC. Further studies using NVDRS data will allow interpretation of broader trends across more states. Analyzing data on the circumstances associated with violent deaths should provide a better understanding of personal and social risk factors for violence and help identify potential prevention opportunities. Reviews of promising strategies conclude that those simultaneously addressing multiple risk factors for violence are most likely to be effective (7) (8) (9) Adverse drug events (ADEs) occur when therapeutic drugs have injurious effects; current systems for conducting national ADE surveillance are limited, and current national estimates of ADE incidence are problematic (1) . In 2003, CDC, in collaboration with the Consumer Product Safety Commission (CPSC) and the Food and Drug Administration (FDA), created the National Electronic Injury Surveillance SystemCooperative Adverse Drug Event Surveillance (NEISS-CADES) project by adding active surveillance of ADEs to the National Electronic Injury Surveillance System -All Injury Program (NEISS-AIP). Because ADEs can be more difficult to identify than other injuries, an independent chart review in a sample of six NEISS-CADES hospitals was conducted to evaluate the sensitivity and predictive value positive (PVP) of ADE identification. This report describes the results of that evaluation, which indicated that although PVP for ADEs was high, the sensitivity was low, particularly for certain types of ADEs. As a result of these findings, additional training on identifying and reporting ADEs was initiated for all NEISS-CADES hospital coders. As more persons in the United States use drug therapies, active, postmarketing surveillance of ADEs can help identify safety problems and guide prevention efforts.
NEISS-CADES is a nationally representative subsample of 64 of 98 NEISS hospitals selected as a stratified probability sample of U.S. hospitals with a minimum of six beds and a 24-hour emergency department (ED) (2) . At each of the 64 hospitals, coders trained by CPSC and CDC staff review all ED charts for ADEs. Coders identify cases by looking for keywords and diagnoses, such as "medication reaction," "overdose," and "adverse effect," and record information into a standardized, computer-based data-entry system. Cases are defined as those occurring in persons who sought ED care for injuries linked by the treating physician to the outpatient use of a drug or drug-specific adverse effects. This case definition excludes drug withdrawal, drug abuse, self-harm attempts, lack of therapeutic effect, and effects of medications administered in the ED. Drugs include prescription medications, over-thecounter medications, vaccines, vitamins, and nutritional supplements.
For this evaluation, a convenience sample of six NEISS-CADES hospitals was selected from 14 hospitals with scheduled site visits in the summer of 2004 and the capability to provide a sufficient number of randomly selected medical charts for review. Hospitals were selected to represent a range of ADE reporting (0.2%-1.7% of ED visits) and a range of hospital sizes* (three very large, one large, one medium, and one small hospital). Large metropolitan (one hospital), smaller metropolitan (three hospitals), and rural areas (two hospitals), † and five of nine U.S. census geographic divisions were represented. The sample did not include any pediatric specialty hospitals. At each hospital, ED charts were retrieved for review from a list of randomly selected dates during the period January 1-June 15, 2004. Up to 1,200 charts or up to 20 days of charts were retrieved on the basis of the ED volume of each hospital. Because of limitations in medical record archiving systems, charts were not retrievable for six (10%) of 61 dates initially selected, and alternate dates were selected as substitutes. Of 4,719 ED visits identified for the dates selected, charts for 4,561 (97%) visits were available for review.
Chart reviewers used the same standardized methodology as coders. Each available chart was reviewed by two reviewers experienced in medical record abstraction and ADE surveillance (i.e., an epidemiologist with training in medical terminology and a physician board-certified in internal medicine) independent of each other and of the NEISS hospital coder. For ADE cases, each reviewer recorded event descriptions and associated drugs. Conflicting reviews were resolved by a third person (a physician board-certified in internal and emergency medicine). A sample kappa statistic was calculated by using statistical software to assess agreement of case identification between the two primary reviewers (3) . Using the review process described in this report as the "gold standard," sensitivity (i.e., the proportion of cases detected by the surveillance system) and PVP (i.e., the proportion of coder-reported cases that actually had a drug-related event) for the six-hospital composite were calculated by using ratio estimation (4). These statistics were calculated as ratio estimates, assuming a stratified cluster sampling design, with hospitals forming strata and dates forming clusters. The charts reviewed from each ED were assigned weights according to the fraction of dates reviewed out of the January 1-June 15 sampling frame and the fraction of cases for which charts were available for each date reviewed.
A total of 68 ADE cases were identified by expert review of the 4,561 ED charts (weighted estimate: 1.4%) (Table) . Ten cases were initially identified by only one of two reviewers (seven identified by one reviewer and three identified by the other), with a sample kappa statistic of 0.92 (95% confidence interval [CI] = 0.87-0.97), indicating a high level of nonchance agreement between reviewers. The median age of patients with ADEs was 57 years (range: 15 months-100 years), and 53% were female.
A total of 29 ADE cases had been reported to NEISS-CADES before the charts were reviewed. Of these, 25 were among the 68 ADE cases detected by the reviewers, whereas the remaining four were false-positive cases in which an injury was attributed to a drug in the chief complaint section of the chart but was not confirmed elsewhere in the chart. The weighted estimate of coder sensitivity for ascertaining ADE cases was 0.33 (CI = 0.23-0.44). The weighted estimate of PVP for coder-reported ADEs was 0.92 (CI = 0.85-1.00). The relatively low overall coder sensitivity was attributed in part to low sensitivity for detecting cases of hypoglycemia associated with diabetes agents (three of 16 detected) and bleeding associated with anticoagulants (e.g., warfarin and heparin) (one of nine detected). When a narrower case definition excluding these two types of cases was considered, weighted sensitivity increased to 0.45 (CI = 0.31-0.59), and weighted PVP was 0.94 (CI = 0.85-1.00). As a result of these findings, NEISS-CADES coders are now provided a streamlined flow sheet to identify ADEs and training specifically focused on identifying unintentional overdoses of diabetes agents and anticoagulants.
Editorial Note: The goal of this evaluation was to assess and improve the usefulness of NEISS-CADES as an ongoing system to provide national estimates of ADEs. Evaluation of new surveillance systems such as NEISS-CADES is a challenging but important task for appropriately interpreting and applying public health surveillance data. If the hospitals in this investigation are representative of other NEISS-CADES hospitals, the PVP of 0.92 indicates that the ADE cases reported 
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in NEISS-CADES generally represent actual cases. The low proportion of cases initially identified that were attributed to overdoses of insulin and anticoagulants suggests that national estimates of these events are likely to be lower than the actual number and highlights areas on which to focus interventions. After the implementation of interventions, reevaluation of sensitivity and PVP will be needed to help further improve sensitivity.
The sensitivity of coder case identification reported in this investigation might appear low (0.33 overall; 0.45 if two specific types of ADEs are excluded); however, this result should be considered in the context of other available surveillance data. The most commonly used national surveillance system for ADEs, the FDA Adverse Event Reporting System (AERS), is a passive surveillance system estimated to capture 1%-38% of serious adverse drug reactions and influenced by such factors as length of time the drug has been on the market and media attention (5) . In addition, AERS was designed to capture newly recognized, unlabeled, adverse events and not designed to capture common ADEs from errors or overprescribing of older drugs, which likely contribute to the greatest public health burden (6) . The National Hospital Ambulatory Medical Care Survey (NHAMCS) (7) has been used to describe outpatient adverse reactions, and the Drug Abuse Warning Network (DAWN) recently modified datacollection procedures to include adverse reactions (8); similar assessment of these systems might be appropriate.
The findings in this report are subject to at least three limitations. First, this evaluation was limited to review of available ED patient charts from a sample of days in six of the 64 NEISS-CADES hospitals. These hospitals were chosen as a convenience sample stratified by ADE reporting and size; therefore, although the characteristics of the ADE cases reported are similar to those from other hospitals (9), the estimates of sensitivity and PVP might not apply to other hospitals. Second, identification of ADEs by chart review has lower sensitivity for some types of ADEs when compared with other methods, such as screening computer-generated laboratory signals (10); however, chart review remains the most feasible method of national surveillance. Finally, surveillance of outpatient ADEs based on ED data does not capture ADEs that were not diagnosed and documented by the treating physician, ADEs diagnosed during subsequent hospitalizations, or ADEs treated elsewhere. Since publication of the Institute of Medicine report, To Err Is Human: Building a Safer Health System, in 1999, considerable attention has been focused on the public health problem of medical injuries and ADEs, especially ADEs that occur in hospitalized patients. However, at least in part because of limited data, the potentially more common problem of ADEs in nonhospitalized persons has not been as fully explored. Nationally representative surveillance data that is both timely and detailed is needed to characterize the public health burden of outpatient ADEs and to help target prevention strategies. NEISS-CADES will continue as a resource for providing ongoing ADE surveillance, and this evaluation will assist in interpretation and use of these public health data.
Congenital Malaria -Nassau County, New York, 2004
Human malaria is a parasitic disease caused by four distinct species of intraerythrocytic protozoa of the genus Plasmodium. The parasites are transmitted to persons by the bite of an infective female Anopheles mosquito and rarely through blood transfusion and congenital transmission (1, 2) . The majority of malarial infections reported in the United States are acquired abroad by recent immigrants or persons returning from areas where malaria is endemic (3, 4) . This report describes the first documented case of congenital malaria acquired in Nassau County, New York, which is the fifth case of congenital malaria reported in the United States since 2000 (5) (6) (7) (8) . Health-care providers should consider malaria as a diagnosis in neonates and young infants, particularly those with fever, whose mothers emigrated from areas where malaria is endemic.
In April 2004, a previously well male infant aged 7 weeks born in Nassau County was hospitalized with a 1-day history of low-grade fever. The infant had been born at full term in an uncomplicated vaginal delivery; birthweight was 6 pounds, 14 ounces, and his APGAR scores were 9/9 (out of 10, at 1 minute and 5 minutes after birth). On admission to the hospital, the infant was placed on antibiotic treatment, and a laboratory evaluation was performed for a presumptive diagnosis of sepsis by using bacterial cultures of blood, urine, and cerebrospinal fluid (CSF) and viral cultures of CSF; however, the cultures yielded negative results, and no cause was identified. On the third day of hospitalization, antibiotics were discontinued, the infant had no fever, and he was discharged. Laboratory testing indicated hemoglobin of 9.2 g/dL (normal: 10.0 g/dL-14.3 g/dL) and a white blood cell count of 6,300 cells/µL (normal: 6,000 cells/µL-17,500 cells/µL).
On follow-up 5 days after discharge, the infant had no symptoms or signs of illness except for a hemoglobin measurement of 6.2 g/dL with a hematocrit of 18% (normal: 29.3%-42.2%). Peripheral smears revealed malarial parasites (parasitemia <1% of red blood cells); morphology was consistent with Plasmodium vivax. The infant was immediately readmitted to the hospital. Treatment with the recommended dose of chloroquine was well tolerated, and the infant was transfused with 75 mL (15 mL/kg of patient body weight) of packed red blood cells before discharge. His hemoglobin at discharge was 11 g/dL, and he had negative smears for malarial parasites.
Investigation by the Nassau County Department of Health revealed that the mother had emigrated from Guatemala in June 2003 and since then had not traveled outside the United States. The risk assessment questionnaire used by her prenatal provider did not include a question regarding history of malaria. In November 2003, during her fifth month of pregnancy, the mother telephoned her health-care provider to report a 1-day history of fever, myalgia, and headache. Two days later, she went to a local emergency department with headache, sore throat, and rhinorrhea. She was discharged with a diagnosis of upper respiratory infection. No laboratory or other studies were performed.
After malaria was diagnosed in the infant, blood was collected from the mother the same day; the sample was negative for malarial parasites on blood films but positive for P. vivax DNA by polymerase chain reaction. She was prescribed chloroquine and primaquine. One month later, the mother was interviewed in Spanish, her native language; she stated that she had malaria diagnosed 2 years earlier in Guatemala and was treated with an unknown therapy. She told interviewers she had one relapse while residing in Guatemala. She could not recall the date of her relapse, nor the type of treatment. Editorial Note: Malarial infection or relapse during pregnancy poses substantial risks to the mother and fetus, including risks for maternal anemia, spontaneous abortion, perinatal mortality, low birthweight, and prematurity (1, 3) . Pregnancy is known to be a common cause of relapse with P. vivax and P. ovale (4) . Recurrences of any partially or improperly treated species of Plasmodium might be caused by the natural immune suppression that is characteristic of pregnancy (8) . Diagnosis can be complicated by the nonspecific clinical presentation of this disease (1, 4) . Practitioners in areas where malaria is not endemic often fail to consider malaria in their initial differential diagnoses (9) . In an immigrant, diagnosis of malaria is further complicated because many immigrants have partial immunity, possibly resulting in longer incubation periods and more subtle, nonspecific symptoms (1). In a newborn, signs and symptoms of malaria, including fever, poor appetite, irritability, and lethargy, can mimic sepsis, further obscuring the diagnosis (3).
According to the Pan American Health Organization, malaria remains endemic in 21 countries of the Americas, including Guatemala, the country of origin for the mother described in this report. P. vivax is the predominant malarious parasite in the Americas, accounting for 71% of cases in the 21 countries with transmission and 97% of cases in Guatemala in 2001 (10) .
Practitioners should ask immigrant patients their country of origin, date of immigration, and dates of any return travel to their home country (4) . Practitioners should also be aware of information resources regarding the global distribution of infectious diseases of clinical importance (http://www.cdc.gov/ travel). In the rare case of congenital transmission described in this report, language and cultural barriers might have posed obstacles to disclosure by the pregnant mother of her history of malaria to her health-care provider. When feasible, medical history forms completed by a patient in any health-care setting should be available in the patient's native language and should include conditions and diseases of epidemiologic importance. CDC recommends that malaria be considered in the differential diagnosis of illness in 1) persons with fever and a history of travel to areas where malaria is endemic, including immigrants, refugees, migrant laborers, and international travelers; 2) fever of unknown origin, regardless of travel history; and 3) ill neonates and young infants, particularly those with fever and immigrant mothers, regardless of the interval between the mother's immigration and delivery (2, 8) . Additional information regarding diagnosis of malaria is available at http://www.dpd.cdc.gov/dpdx. Among the 16.5% of persons aged <65 years who were without health insurance at the time of the interview, approximately one fourth had never had health insurance, and an additional one fourth had been without health insurance for >36 months. Being without health insurance for a lengthy period is associated with less access to preventive healthcare services and decreased continuity of care for chronic conditions. Notice to Readers
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Africa Malaria Day -April 25, 2005
Every 30 seconds, a child in Africa dies from malaria; of the estimated 1 million malaria deaths occurring each year worldwide, 90% occur in Africa, primarily among young children (1, 2) 
The Abuja goal is achievable; malaria is preventable and curable, effective tools and strategies are already used to combat malaria (e.g., drugs, insecticide-treated bed nets, and indoor insecticide spraying), research is under way to improve current tools and strategies and develop new ones (e.g., vaccines), and the global community offers increasing financial and technical support to fight malaria.
To mark Africa Malaria Day 2005, major events will be held in locations worldwide, including Lusaka, Zambia; Washington, DC; and Brussels, Belgium. This year's theme, "Unite Against Malaria," and the associated slogan, "Together We Can Beat Malaria," underscore the importance of collaboration among all stakeholders, as exemplified by the Roll Back Malaria Partnership, a global partnership initiated by the World Health Organization, United Nations Development Programme, United Nations Children's Fund, and World Bank in 1998, that works with governments, other development agencies, nongovernmental organizations, and private-sector companies to reduce the human and socioeconomic costs of malaria.
Africa Malaria Day 2005 is also an occasion to take stock of progress midway to the 2010 goal. The Abuja Declaration proposed an intermediate target to be reached by 2005: 60% of people suffering from, or at risk for, malaria having access to treatment and protective measures. Evaluating the extent to which this interim target has been reached will guide efforts toward halving malaria deaths by 2010. 
Notice to Readers

Autism Awareness Month -April 2005
April is Autism Awareness Month. Autism spectrum disorders are lifelong developmental disabilities characterized by unusual social and communication development and the presence of unusual or repetitive behaviors and interests (1) . These conditions affect as many as 2-6 per 1,000 children in the United States (2,3), making autism a serious public health concern. Children with autism identified early and enrolled in early intervention programs show significant improvements in their language, cognitive, social, and motor skills, as well as in their future educational placement (4, 5) . In collaboration with a coalition of partners, CDC recently launched a public awareness campaign, "Learn the Signs. Act Early." to educate parents about early childhood development, including potential early warning signs of autism and other developmental disabilities.
To track rates and trends in autism and conduct epidemiologic studies, CDC funds monitoring programs in 18 states and supports five Centers for Autism and Developmental Disabilities Research and Epidemiology (CADDRE). The CADDRE centers are conducting a large-scale, epidemiologic case-control study of autism to examine potential risk factors. Additional information about autism activities is available at http://www.cdc.gov/ ncbddd/autism or http://www.cdc.gov/actearly.
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Notice to Readers
National STD Awareness MonthApril 2005
April is National Sexually Transmitted Diseases (STDs) Awareness Month, a health observance created to increase awareness about STDs, including their transmission, prevention, and treatment. STDs continue to be a major health threat in the United States, especially among adolescents and young adults. CDC estimates that 19 million new STD infections occur annually, nearly half of them among persons aged 15-24 years (1). Untreated STDs can lead to potentially severe and costly health consequences. Annual direct medical costs of STDs among persons aged 15-24 years are estimated at $6.5 billion (2).
STDs are preventable, and many are easily treated and cured. However, the majority of adolescents and young adults are not adequately screened for STDs. This is especially true for two of the most common STDs, chlamydia and gonorrhea. Both are easily treated, but because they are often asymptomatic (especially in females), screening is necessary to detect infection. In 2003, only 29% of young women aged 16-25 years in commercial managed health-care plans were screened for chlamydia, compared with breast and cervical cancer screening rates of approximately 75% (3). CDC and professional organizations such as the American Medical Association recommend that all sexually active women aged <25 years receive screening for chlamydia each year (4). Advances in diagnostic technology, including tests that can evaluate urine and vaginal swab specimens, enable screening for STDs in various settings, including school-based clinics and community-based organizations. Additional information regarding chlamydia and other STDs is available at http://www.cdc.gov/std. Notice to Readers
CDC Announces Landmark Reorganization
As the world copes with 21st-century health threats such as terrorism, avian influenza, and the unrelenting stresses of modern life, CDC has taken a landmark step in its readiness to confront these challenges. After notification by the U.S. Department of Health and Human Services on April 5, 2005, the U.S. Congress officially accepted CDC's plans for internal restructuring, making it official on April 21. These proposed changes will enable CDC to pursue its mission in preparing for new and unpredictable health threats and protecting the health and quality of life of all U.S. residents throughout their lives.
CDC is also changing to keep up with more complex health concerns such as childhood asthma, AIDS, catastrophic natural disasters, and a barrage of global health threats. During its most recent major transformation nearly 20 years ago, CDC had approximately 4,000 employees and a budget of $411 million. Today, its combined workforce of employees and contractors totals nearly 14,000, with a budget of approximately $8 billion. The agency is changing to meet 21st-century challenges such as new technology, complex information flow, and rising health-care costs. Change also includes modernizing its management and accountability to realize tangible savings that can go directly to science and programs that affect public health.
This modernization involves a new organizational structure, including a framework for four new coordinating centers that will help CDC scientists combine their expertise to solve public health problems, streamline the flow of information for leadership decision-making, and better leverage the expertise of CDC partners. CDC has also added two new centers to focus on health informatics and health marketing, which are vital in translating scientific data into usable information and health messages that help U.S. residents make sound health decisions. Additional information about the reorganization of CDC is available at http://www.cdc.gov/od/oc/media. On page 247, in Figure 1 , errors occurred in the shading used to indicate the rate range groups for three states. The shading should indicate the following: Maine, <1.7 per 100,000 population; New Hampshire, 1.8-2.8; and Pennsylvania, 1.8-2.8.
Erratum: Vol. 54, No. 14
In the QuickStats, "Life Expectancy at Birth, by YearUnited States, 1970-2003," on page 363, the ethnic identifier "non-Hispanic" was incorrectly used to describe the four populations represented in the figure. The populations should have been described as: white female, black female, white male, and black male. Persons in these populations were of any ethnicity. 
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